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Purpose: Recent studies have shown that cyclooxygenase (COX)-2 may be involved in tumor growth, invasion and apop-
tosis in various carcinomas. Vascular endothelial growth factor (VEGF) has a potent angiogenic activity, and COX-2 pro-
motes angiogenesis by modulating angiogenic factors, including VEGF. Endothelial growth factor receptor (EGFR) is con-
sidered as a factor of cell growth, maturation and cell death. The current study was designed to investigate the possible roles 
of COX-2 in colorectal tumor progression and angiogenesis. 
Methods: Fifty colorectal adenomas and forty adenocarcinomas were investigated by using immunohistochemical stain-
ing for COX-2, VEGF and EGFR. The correlations of COX-2, VEGF and EGFR with the grade of dysplasia, the size of the 
adenoma, and various clinicopathologic factors were studied. 
Results: The expressions of COX-2, VEGF and EGFR were each significantly correlated with carcinomatous transforma-
tion, and the expressions of COX-2 and VEGF were significantly correlated. COX-2 and EGFR showed correlations with 
adenomas rather than adenocarcinomas. However, no correlations of COX-2, VEGF and EGFR expression to other clini-
copathologic factors, except tumor size in EGFR expression, were detected. 
Conclusion: These results suggest that COX-2 may play an important role in carcinogenesis through interaction with VEGF 
and EGFR in human colorectal cancer.  
Keywords: Cyclooxygenase 2; Vascular endothelial growth factor; Endothelial growth factor receptor; Colorectal carcinoma; 
Adenocarcinoma 
cyclooxygenase (COX), the rate limiting enzyme of the ara-
chidonic acid metabolism. COX is a key enzyme converting 
arachidonic acid to eicosanoids, including PG, and the pro-
duced PGs mediate complex biological functions in vivo [2, 4]. 
COX can be classified into two isozymes, COX-1 and COX-2. 
COX-1 is expressed in a constant concentration in most nor-
mal cells, and it is involved in the protection of the gastric mu-
cosal epithelium, the maintenance of renal plasma and the reg-
ulation of platelet aggregation. COX-2 is rarely expressed in 
normal cells, it is induced by stimulations of cytokines, growth 
factors, hormones, mitosis, and it has been revealed to be ex-
pressed in inflammatory cells or cancer cells. COX-2 selective 
inhibitors have been used as therapeutic agents for arthritis 
without pre-existing gastrointestinal disturbance or anti-in-
flammatory agents [4, 5].
In previous experimental studies, nonsteroidal antiinflam-
INTRODUCTION
The concentration of prostaglandin (PG) has been found to be 
increased in several cancers, and studies on the effect of PG 
and its metabolites on the growth and metastasis of cancer are 
ongoing actively [1-3]. PG is produced through the action of 
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matory drugs (NSAID) have been reported to reduce the in-
cidence of colon polyps and colon cancers [6, 7], induce the 
degeneration of breast cancer [8], and suppress the growth of 
tumors in the neck [9]. The mechanism of NSAID suppress-
ing the development of colon cancer has not been elucidated 
yet; nonetheless, it is thought to reduce the production of PG 
by interfering with COX activity and to exert effects on cell 
growth, apoptosis and immune reactions [3, 10]. Nevertheless, 
clinical studies have revealed that COX inhibitors, including 
NSAID, are restricted to use as therapeutics because of gastro-
intestinal disturbance and cardiovascular impairments [11].
Recently, correlations between the expression of COX-2 and 
other oncogenic factors associated with tumor growth and dis-
tant metastasis have become an issue; thus, attention has been 
paid to COX-2 as a prognostic factor. The overexpression of 
COX-2 has been reported to affect the regulation of the angio-
genesis of tumors by being involved in the synthesis of various 
angiogenic factors, such as vascular endothelial growth factor 
(VEGF) and epidermal growth factor receptor (EGFR), and 
thus to play an important role in the growth and progression of 
tumors [12, 13]. Tumor angiogenesis is an important factor for 
tumor growth, infiltration and metastasis (when solid tumors 
grow, they induce vascular stroma), and the level of vascular-
ized stroma has been reported to be closely associate with prog-
nosis [14]. Among several angiogenesis factors, VEGF and EGFR 
have been reported to be overexpressed not only in colorectal 
cancer but also in several other tumors [15-17].
In stomach cancer, breast cancer, head and neck cancer, and 
colorectal cancer, several studies on the association of COX-2, 
VEGF, and EGFR with angiogenesis have already been reported 
[13, 15-18]. Nonetheless, such reports on colorectal adenomas 
and carcinomas are rare; thus, in our study, the expressions of 
COX-2, VEGF, and EGFR in colorectal adenomas and carci-
nomas were examined by using immunohistochemical stain-
ing to find the differences in the expressions according to the 
histological differentiation grade and the tumor size. Also, 
whether COX-2 is associated with angiogenesis and thus plays 
a role in the development and growth of colorectal cancer and 
the mechanism of metastasis, and its role as a prognostic fac-
tor were investigated.
METHODS
Patients 
Patients with pathologically proven colorectal adenomas or 
carcinomas from January 2003 to June 2004 at the National 
Health Insurance Corporation, Ilsan hospital, were included 
in this study. Fifty patients on whom a polypectomy or an en-
doscopic mucosal resection had been performed were selected 
from among the colorectal adenoma patients admitted to the 
Department of Gastrointestinal Medicine, and 40 patients were 
selected from among colorectal cancer patients who under-
went surgery in the Department of Surgery. Among the 50 
cases of colorectal adenoma, 38 cases were low grade dyspla-
sia and 12 cases showed high grade dysplasia; 43 cases were 
tubular adenomas, 6 cases were tubulovillous adenomas, and 
1 case was a serrated adenoma. Among the 38 cases showing 
low grade dysplasia, 15 patients had lesions smaller than 5 
mm, and 23 patients had lesions larger than 5 mm.
The clinical records of the patients were examined, and clin-
ical findings associated with prognosis, such as age, gender, 
clinical stage, etc., were examined. By reviewing pathological 
reports and slides with H&E staining, the sizes and locations 
of the lesions in the extracted tissues were assessed and histo-
logical types, differentiation grades, and the presence or ab-
sence of adjacent lymph node metastasis were reconfirmed. 
The pathological stage was classified according to the TNM 
stage of the American Joint Committee on Cancer. 
Immunohistochemical staining and interpretation
The most appropriate paraffin block of each case was selected, 
and according to the avidin-biotin complex method, immu-
nohistochemical staining for COX-2, VEGF, and EGFR was 
performed. Paraffin-embedded samples were sectioned, depa-
raffined, rehydrated with ethanol, and treated with 3% hydro-
gen peroxide solution for 10 minutes at room temperature to 
suppress endogenous peroxidase. Antigen retrieval was per-
formed by using microwaves. The samples were treated with 
blocking antibody and were subsequently incubated with the 
primary antibody to COX-2, EGFR (1:100, Zymed, San Fran-
cisco, CA, USA) or VEGF (1:400, BD Pharmingen, San Diego, 
CA, USA) at 4°C overnight. On the next day, the samples were 
washed with Tris buffer for 10 minutes, treated with the second-
ary antibody and streptavidin-peroxidase conjugate, stained 
with diaminobenzidine, counterstained with Mayer’s hema-
toxylin, and examined under a microscope. The results were 
interpreted by two pathologists independently. If their inter-
pretations were not in agreement, they re-examined the cor-
responding slide together and made a determination. 
The staining of COX-2 was scored as follows: 0, cells without 
staining in the cytoplasm; 1, less than 50% of the cells with mild 
or moderate staining in the cytoplasm; 2, more than 50% of the 
cells with mild or moderate staining or less than 50% of the 
cells with strong staining in the cytoplasm; 3, more than 50% 
of the cells with strong staining in the neoplasm. Cases with 
more than 2 points were determined as positive. The interpre-
tations of the results of VEGF or EGFR staining were based on 
a semi-quantitative analysis. The samples were divided into 4 
levels: cases were 0 points, cases with less than 10% positive cells 
were 1 point, cases with 10-50% positive cells were 2 points, 
and cases with more than 50% positive cells were 3 points. Cases 
with more than 2 points were considered to be positive. The 
positive control for COX-2, VEGF, and EGFR was gastric ad-
enocarcinoma, and the negative control was the normal mu-Journal of The Korean Society of
Coloproctology
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cosa around tumors on the same slide. 
Statistical analysis 
All statistical analyses were performed with the χ²-test or the 
Fisher’s exact test by using the SPSS (SPSS Inc., Chicago, IL, 
USA). P-values < 0.05 were considered to indicate statistically 
significant differences.
RESULTS
Expression of COX-2 in colorectal adenomas and 
carcinomas
In colorectal adenomas and carcinomas, COX-2 was primar-
ily expressed in the cytoplasm as a diffuse or microgranular 
pattern. The pattern was the weak staining of some adjacent 
interstitial cells or inflammatory cells and was not detected in 
the normal mucosal epithelium (Fig. 1A). Particularly, in can-
cer cell clusters, the infiltrative border showed stronger stain-
ing patterns than the center area (Fig. 1B). 
In regard to the expression levels of COX-2 in the 50 cases 
of colorectal adenomas, 10 cases had 0 points, 9 cases had 1 
point, 15 cases had 2 points, and 6 cases had 3 points. Accord-
ing to the differentiation grade of the adenoma, the COX-2 
positive rate in the high grade dysplasia cases was 66.7%, and 
it was shown to be higher than the 34.2% for low grade dys-
plasia cases. Among the low grade dysplasia cases, according 
to the size of the tumor, the COX-2 positive rate in tumors 
with sizes larger than 5 mm was 43.4%, and that in tumors 
with sizes smaller than 5 mm was 20%, but this difference did 
not show statistical significance (P > 0.05). The COX-2 posi-
tive rate in colorectal carcinomas was shown to be high, 80%, 
and it was statistically significantly higher than the 44% posi-
tive rate for adenoma cases (P < 0.05) (Table 1). 
Expression of VEGF in colorectal adenomas and 
carcinomas 
In colorectal adenomas and carcinomas, VEGF was expressed 
limitedly in the cytoplasm and cell membrane, and it was stained 
more strongly in the infiltrative area of the carcinoma (Fig. 2). 
In addition, it was stained weakly in vascular endothelial cells, 
inflammatory cells, and interstitial cells. 
The positive expression rate of VEGF in colorectal adenomas 
was 28%, and in colorectal carcinoma, it was 75%, this differ-
ence being statistically significant (P < 0.05). Similar to COX-
2, the expressions according to the histological dysplasia level 
of colorectal cancer or according to tumor size did not show 
significant differences (P > 0.05) (Table 2). In colorectal ade-
nomas, the positive rate in high grade dysplasia cases was 50%, 
and in low grade dysplasia cases, it was 26.4%. In low grade 
dysplasia cases, according to tumor size, the positive rate in 
A B
Fig. 1. (A) Cyclooxygenase-2 (COX-2) expression in the dysplastic epithelium as weak and diffuse (immunohistochemistry, × 100). (B) COX-2 
expression in an adenocarcinoma as strong and diffuse (immunohistochemistry, × 100).
Table 1. COX-2 expression in colorectal adenomas and adenocarci-
nomas
Histology & size
Total  
(n = 90)
COX-2 score (%)
0 1 2 3
(-) (+)
Adenoma
a 50 10 (20) 19 (38) 15 (30) 6 (12)
   LGD
b (mm)
      < 5
c
      ≥ 5
d 
15
23
6
3
  6
10
3
7
0
3
   HGD
e 12 1   3 5 3
Adenocarcinoma
f 40 0 (0) 8 (20) 18 (45) 14 (35)
COX-2, cyclooxygenase-2; LGD, low grade dysplasia; HGD, high grade 
dysplasia.
a,fP < 0.05; 
b,eP > 0.05; 
c,dP > 0.05. Journal of The Korean Society of
Coloproctology
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cases with sizes larger than 5 mm was 26.1%, and that in cases 
with sizes smaller than 5 mm was 13.3%. 
Expression of EGFR in colorectal adenomas and carcinomas
In colorectal adenomas and carcinomas, EGFR was expressed 
limitedly in the cytoplasm and cell membrane of tumor cells. 
In adenomas, it was expressed weakly, or only in some areas 
as a diffuse pattern, (Fig. 3A, 3B). In carcinomas, it was stained 
strongly as a diffuse pattern (Fig. 3C). In colorectal adenomas, 
the positive rate of expression of EGFR was 24%, and in colorec-
tal carcinomas, it was 60%; this was a statistically significant 
difference (P < 0.05). In regard to the expression level of EGFR 
according to the histological dysplasia of the colorectal ade-
noma and according to the tumor size, similar to COX-2, no 
significant differences were observed (Table 3). Among ade-
nomas, the positive rate in high grade dysplasia cases was 50%, 
and that in low grade dysplasia cases was 15.8%. Among low 
grade dysplasia cases, according to tumor size, the positive rate 
in cases with tumors larger than 5 mm was 21.7%, and that in 
cases with tumor sizes smaller than 5 mm was 7%. 
Relation of the expression of COX-2 with VEGF  
in colorectal adenomas and carcinomas 
In colorectal adenomas and carcinomas, the expression of 
COX-2 was related with that of VEGF, and that relation was 
statistically significant (Table 4). 
Relation of the expression of COX-2 with EGFR  
in colorectal adenomas and carcinomas 
The relation of the expression of COX-2 with EGFR was sta-
tistically significant in adenomas. Nonetheless, in carcinomas, 
with or without the expression of COX-2, COX-2 expression 
A B
Fig. 2. (A) Vascular endothelial growth factor (VEGF) expression in the dysplastic epithelium as moderate and diffuse (immunohistochemis-
try). (B) VEGF expression in an adenocarcinoma as strong and focal (immunohistochemistry, × 100).
Table 3. EGFR expression in colorectal adenomas and adenocarci-
nomas
Histology & size
Total  
(n = 90)
EGFR score (%)
0 1 2 3
(-) (+)
Adenoma
a 50 22 (44) 16 (32) 8 (16) 4 (8)
   LGD
b (mm)
      < 5
c
      ≥ 5
d 
15
23
11
10
3
8
1
4
0
1
   HGD
e 12   1 5 3 3
Adenocarcinoma
f 40 7 (17.5) 9 (22.5) 13 (32.5) 11 (27.5)
EGFR, endothelial growth factor receptor; LGD, low grade dysplasia; 
HGD, high grade dysplasia.
a,fP < 0.05; 
b,eP > 0.05; 
c,dP > 0.05. 
Table 2. VEGF expression in colorectal adenomas and adenocarci-
nomas 
Histology & size
Total  
(n = 90)
VEGF score (%)
0 1 2 3
(-) (+)
Adenoma
a 50 18 (36) 18 (36) 10 (20) 4 (8)
   LGD
b (mm)
      < 5
c
      ≥ 5
d 
15
23
9
6
  4
11
2
4
0
2
   HGD
e 12 3   3 4 2
Adenocarcinoma
f 40 1 (25) 9 (22.5) 16 (40) 14 (35)
VEGF, vascular endothelial growth factor; LGD, low grade dysplasia; 
HGD, ligh grade dysplasia.
a,fP < 0.05; 
b,eP > 0.05; 
c,dP > 0.05.Journal of The Korean Society of
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agreed with EGFR expression in 65% of the cases (26/40), but 
this difference was not statistically significant (Table 5). 
Correlations of the expressions of COX-2, VEGF and EGFR 
to clinicopathological factors in colorectal carcinomas 
In colorectal carcinoma, no statistically significant differences 
were noted in the analysis of the correlations of the expressions 
of COX-2 and VEGF to age, gender, tumor size, the existence 
or absence lymph node metastasis, histological differentiation 
grade, or pathological stage, although the expression rate was 
high in elderly males, cases with tumors larger than 5 cm, cases 
C
A B
Fig. 3. (A) Mild diffuse expression of endothelial growth factor re-
ceptor (EGFR) in an adenoma (immunohistochemistry, × 40). (B) 
Aberrant expression of EGFR in an adenoma (immunohistochemis-
try, × 40). (C) Increased expression of EGFR in an adenocarcinoma 
(immunohistochemistry, × 100).
Table 4. Correlation between COX-2 & VEGF expressions in colorec-
tal adenomas and adenocarcinomas
Histology
COX-2  
expression
VEGF expression  P- 
value (-) (+)
Adenoma
(n = 50)  (-)  (n = 29)
 (+)  (n = 21)
(n = 36)
24
12
(n = 14)
  5
  9  < 0.05
Adenocarcinoma
(n = 40) (-)  (n = 8)
  (+)  (n = 32)
(n = 10)
  6
  4
(n = 30)
  2
28  < 0.05
COX-2, cyclooxygenase-2; VEGF, vascular endothelial growth factor.
Table 5. Correlation between COX-2 & EGFR expressions in colorec-
tal adenomas and adenocarcinomas
Histology
COX-2  
expression
EGFR expression  P- 
value
(-) (+)
Adenoma
(n = 50)   (-)  (n = 29)
  (+)  (n = 21)
(n = 38)
29
  9
(n = 12)
  0
12  < 0.05
Adenocarcinoma
(n = 40) (-)  (n = 8)
  (+)  (n = 32)
(n = 16)
  5
11
(n = 24)
  3
21  > 0.05
COX-2, cyclooxygenase-2; EGFR, endothelial growth factor receptor.Journal of The Korean Society of
Coloproctology
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with lymph node metastasis, and cases with tumors higher than 
moderate histological grade. The expression of EGFR was shown 
to be statistically significantly higher in tumors with sizes larger 
than 5 cm and in cases with lymph node metastasis. No sig-
nificant correlations to other clinicopathological factors were 
noted (Table 6).
DISCUSSION
With the change to a westernized diet, colorectal cancer has 
become one of cancers rapidly increasing in Korea. Since COX- 
2 has been suggested to be closely associated with the devel-
opment of colorectal cancer, a very important task is to eluci-
date differences between the expressions of COX in colorectal 
adenomas and carcinomas, the roles of those differences dur-
ing the tumor progression process, and their association with 
prognostic factors. 
COX-2 has been shown not to be expressed in the large in-
testinal mucosa, but its expression is increased in colorectal 
cancer [19]. In colorectal cancer, the expression of COX-2 in 
epithelial cells has been reported to alter their cohesiveness and 
to render them resistant to apoptosis, thus accelerating tumor 
growth and infiltration [20]. The precise role of COX-2 in the 
oncogenic course has not yet been elucidated; nevertheless, 
Table 6. Correlations of COX-2, VEGF & EGFR expressions with the clinicopathological parameters in colorectal adenocarcinomas
Clinicopathological 
parameters
Total  
(n = 40)
Cox-2 expression
a VEGF expression
b EGFR expression
c
(+) (n = 32) (-) (n = 8) (+) (n = 30) (-) (n = 10) (+) (n = 24) (-) (n = 16)
Age (yr)
   < 60
   ≥ 60
17
23
15
17
2
6
13
17
4
6
13
11
  4
12
Sex
   Male
   Female
24
16
19
13
4
4
19
11
5
5
14
10
10
  6
Tumor size (cm)
d
   < 5 
   ≥ 5 
18
22
15
17
3
5
14
16
4
6
  5
19
13
  3
LN metastasis
   (+)
   (-)
17
23
13
19
4
4
11
19
6
4
12
12
  5
11
Histologic grade
   Well
   Moderate
   Poor 
  8
22
10
  6
18
  8
2
4
2
  5
17
  8
3
5
2
  4
14
  6
  4
  8
  4
Depth of invasion
   T1
   T2
   T3
   T4
  6
  8
22
  4
  3
  7
19
  3
3
1
3
1
  4
  6
18
  2
2
2
4
2
  1
  2
18
  3
  5
  6
  4
  1
COX-2, cyclooxygenase-2; VEGF, vascular endothelial growth factor; EGFR, endothelial growth factor receptor.
a,b,cOverall P > 0.05; 
dP < 0.05 in EGFR expression. 
Tsujii and DuBois [20] observed that when rat intestinal epi-
thelium was stably transfected with a COX-2 expressing vec-
tor, the cohesiveness of the cells to the extracellular matrix was 
increased, and resistance to natural death was increased; thus, 
they reported that such processes were closely associated with 
the development of colorectal cancer. In addition, it was proven 
that such changes could be reverted to the original condition 
by COX-2 selective inhibitors. Also, COX-2 has been reported 
to be involved in angiogenesis factors, such as VEGF and the 
neovascularization of tumor cells, and such changes could also 
be prevented by COX-2 selective inhibitors [21, 22]. Review-
ing the reports on COX-2 in colorectal tumors, first, the ex-
pression rate of COX-2 in colorectal cancer has been reported 
to be 85-100% [19, 23, 24]. In colorectal adenomas and colorec-
tal cancer, the expression of COX-2 has been reported to be 
elevated in proportion to the size of the tumor, and in colorec-
tal sporadic adenomas, when the lesion was larger than 5 mm, 
the expression of COX-2 was significantly increased [25, 26]. 
Uefuji et al. [27] reported that in the analysis of COX-2 mRNA 
in gastric adenomas and gastric carcinomas, the expression of 
COX-2 correlated to the depth of tumor infiltration, the tumor 
size, and lymph node metastasis. It has been suggested that 
COX-2 induces tumor infiltration or metastasis through the 
COX-dependent PGE2 synthesis process and that it could sup-Journal of The Korean Society of
Coloproctology
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press local tumor immunity. In our study, although it was not 
statistically significant, in colorectal adenomas, the expression 
rate of COX-2 in high grade dysplasia cases (66.7%) was higher 
than it was in low grade dysplasia cases (34.2%), and in low 
grade dysplasia adenomas larger than 5 mm, the expression 
rate was higher than it was in low grade dysplasia adenomas 
smaller than 5 mm (43.4% vs. 20%). However, a statistically 
significant high expression rate was shown in carcinomas in 
comparison with adenomas (80% vs. 44%). Although the num-
ber of cases was not large, this result is thought to support COX-2 
beung induced in the early developmental stage in colorectal 
tumors. Such results of the association of the size of he ade-
noma with dysplasia are almost in agreement with previous 
studies [25, 26, 28]; nonetheless, it has been also reported that 
differences according to histological dysplasia have not been 
detected [29].
The expression of VEGF was similar to the pattern for the 
expression of COX-2. It was shown to be high in high grade 
adenomas larger than 5 mm, it was expressed at a higher rate 
in carcinomaa, and a significant difference was shown. This 
suggests the possibility that the induction of angiogenic fac-
tors and neovascularization are involved from the early devel-
opmental stage. In addition, in our study, in colorectal adeno-
mas and carcinomas, the expression rate of COX-2 was proven 
to be correlated with the expression rate of VEGF, which result 
supports the role of COX-2 reported in other studies; i.e., it 
contributes to the vascularization within cancer by inducing 
the proliferation of vascular endothelial cells and controlling 
the blood flow within tumors. Nevertheless, in other studies, 
when COX-2 is overexpressed, a tendency of increased lymph 
node metastasis and early recurrence has been reported [12, 
24]. In our study, in colorectal cancer, no association of the 
expression of COX-2 or VEGF with other clinical and patho-
logical factors (age, gender, tumor size, presence or absence 
lymph node metastasis, histological differentiation grade, and 
pathological stage) was detected. With the accumulation of 
more cases, the further analysis related to carcinoma site and 
the histological type of the adenoma should be considered.
EGFR has drawn attention as a factor involved in the progres-
sion of cancer and metastasis, and it has been known to be in-
volved in dysplasia from the relatively early phase [15, 30]. In 
our study, the expression of EGFR was similar to the expres-
sion of COX-2 and VEGF; nonetheless, in colorectal cancer, no 
correlation of the expression of COX-2 to EGFR could be de-
tected. Although the expression of COX-2 agreed with the ex-
pression of EGFR in 65% of the cases, this agreement was not 
statistically significant. This may be due to the fact that in regard 
to the expression of EGFR, in addition to PGE2, various other 
factors, such as h-catenin, activator, protein-1, early growth 
response-1 gene, interferon-regulatory factor-1, p53, etc., may 
be involved [30], and the number of subjects was small. How-
ever, in colorectal adenomas, the expression of COX-2 was 
shown to correlate to the expression of EGFR, which may sug-
gest the possibility of a mutual interaction between the two 
factors in the relatively early phase of tumor development. In 
addition, in colorectal adenomas, when tumor size was larger 
than 5 cm, the expression of EGFR was high, which suggests 
the possibility EGFR being a prognostic factor. 
In our study, in colorectal adenomas, the expression of COX-2 
was associated with the level of histological dysplasia and tu-
mor size, and in the early phase of tumor development and 
the growth stage, the induction of COX-2 may be associated 
with the progression of the tumor. The correlation of the ex-
pression of VEGF to the expression of EGFR suggests the pos-
sibility that besides tumor development and growth, COX-2 
may be involved in the cancer’s acquiring an infiltrative, as well 
as metastatic, potential through the interaction of other onco-
genic factors. Therefore, in the future, as prophylactic chemo-
therapies become more important in colorectal cancer, studies 
on prophylactic chemotherapy using drugs selectively suppress-
ing COX-2 and other related oncogenic factors and on the role 
of COX-2 as a prognostic factor should continue to be con-
ducted with more cases. 
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